Abstract:Abstract Background: Erosive esophagitis (EE) is a gastroesophageal reflux disease characterized by mucosal breaks in the esophagus. Proton pump inhibitors are widely used as maintenance therapy for EE, but many patients still relapse. In this trial, we evaluated the noninferiority of vonoprazan vs. lansoprazole as maintenance therapy in patients with healed EE. Methods: We performed a double-blind, double-dummy, multicenter, phase 3 clinical trial among non-Japanese Asian adults with endoscopically confirmed healed EE from April 2015 to February 2019. Patients from China, South Korea, and Malaysia were randomized to vonoprazan 10 mg or 20 mg once daily or lansoprazole 15 mg once daily for 24 weeks. The primary endpoint was endoscopically confirmed EE recurrence rate over 24 weeks with a noninferiority margin of 10% using a two-sided 95% confidence interval (CI). Treatment-emergent adverse events (TEAEs) were recorded. Results: Among 703 patients, EE recurrence was observed in 24/181 (13.3%) and 21/171 (12.3%) patients receiving vonoprazan 10 mg or 20 mg, respectively, and 47/184 (25.5%) patients receiving lansoprazole (differences: –12.3% [95% CI, –20.3% to –4.3%] and –13.3% [95% CI, –21.3% to –5.3%], respectively), meeting the primary endpoint of noninferiority to lansoprazole in preventing EE recurrence at 24 weeks. Evidence of superiority (upper bound of 95% CI <0%) was also observed. At 12 weeks, endoscopically confirmed EE recurrence was observed in 5/18, 2/20, and 7/20 of patients receiving vonoprazan 10 mg, vonoprazan 20 mg, and lansoprazole, respectively. TEAEs were experienced by 66.8% (157/235), 69.0% (156/226), and 65.3% (158/242) of patients receiving vonoprazan 10 mg, vonoprazan 20 mg, and lansoprazole, respectively. The most common TEAE was upper respiratory tract infection in 12.8% (30/235) and 12.8% (29/226) patients in vonoprazan 10 mg and 20 mg groups, respectively and 8.7% (21/242) patients in lansoprazole group. Conclusion: Vonoprazan maintenance therapy was well-tolerated and noninferior to lansoprazole for preventing EE recurrence in Asian patients with healed EE. Trial Registration: https://clinicaltrials.gov; NCT02388737.

Proton Pump Inhibitor Maintenance Therapy in the Prevention of Recurrent Duodenal Ulcer

Effieacy of rabeprazole in freating patients with duodenal ulcer and its effect gastric parietal cell density

Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-Blind, Randomised Trial.

Efficacy of Long-Term Maintenance Therapy with 10-Mg Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis

Efficacy of Esomeprazole in Combination with Levofloxacin and Amoxicillin in Treatment of Helicobacter Pylori-Associated Duodenal Ulcer

Meta-analysis of proton pump inhibitor for preventing recurrence of non-steroidal anti-inflammatory drags-induced ulcers

The Relationship Between Ulcer Recurrence and Helicobacter Pylori : A Prospective One-Year Follow-Up Study in China

A 12‐month Follow‐up Study on the Preventive Effect of Oral Lansoprazole on Acute Exacerbation of Chronic Obstructive Pulmonary Disease

One-Week Antibiotics versus Maintenance Acid Suppression Therapy for Helicobacter pylori-Associated Peptic Ulcer Bleeding

Therapeutic Management of Recurrent Peptic Ulcer Disease

Pantoprazole effectively treats Helicobacter pylori - associated duodenal ulcer

Study on Effect of Omeprazole, Pantoprazole and Lansoprazole in Preventing Stress Ulcer

Initial Treatment With Lansoprazole in Young Dyspeptic Patients With Negative Urea Breath Test Result: A Randomized Controlled Trial With 12-Month Follow-Up

Three-day Lansoprazole Quadruple Therapy for Helicobacter Pylori Positive Duodanal Ulcers: A Randomized Controlled Study

Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial

Efficacy and safety of vonoprazan versus proton pump inhibitors in the treatment of peptic ulcer disease: a systematic review and network meta-analysis for randomized controlled trails

Effect of Lansoprazole and Omeprazole on MDA, SOD and NO Levels in Treatment of Gastric Ulcer

Standard-Dose Proton Pump Inhibitors in the Initial Non-eradication Treatment of Duodenal Ulcer: Systematic Review, Network Meta-Analysis, and Cost-Effectiveness Analysis.

Prospective Randomized Trial of H-Pylori Eradication Versus Maintenance Omeprazole to Prevent Recurrent Upper Gastrointestinal Hemorrhage in High-Risk Aspirin and Non-Aspirin Nsaid Users.

Efficacy and Safety of Vonoprazan-Based Quadruple Therapy for the Eradication of Helicobacter pylori in Patients with Peptic Ulcers: A Pooled Analysis of Two Randomized, Double-Blind, Double-Dummy, Phase 3 Trials

Clinical Study of Two Differential Esomeprazole-based One-week Triple Therapy Regimens for Duodenal Ulcer with Helicobacter Pylori Infection